• Latest Posts
Podcast 1 Sep 2023

Beyond Biotech podcast 61 – Blood Cancer Awareness Month

Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal

Cancer Immunotherapy Phase I on Hold After Patient Death

What Cancer Therapies did European Biotechs Showcase at ASCO 2017?

The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

7 Trendy European Biotechs Listed on the NASDAQ in 2016


Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

Secret Shareholder racks up another €19.2M for Affimed’s Cancer Tandem Antibodies

Affimed secures almost $30M in Financing to continue its clinical development